Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025 Commercial launch in the PRC of generic nintedanib for ...

圣地亚哥 - Gyre Therapeutics（纳斯达克代码：GYRE）公布第四季度营收为$27.87 million，同时给出的2025年全年营收指引低于分析师预期。 这家专注于器官纤维化治疗的商业化生物科技公司预计2025年营收在$118 million至$128 million之间。这一预期相比2024年增长11.3%至20.8%，但低于分析师预期的$135.7 million。

Reports Q4 revenue $ $27.87M consensus $23.5M…”2025 is shaping up to be a pivotal year for Gyre across both our commercial-stage and ...

Idiopathic pulmonary fibrosis is a progressive and life-threatening lung disease but there are ASX companies bringing hope to ...

After hours: March 17 at 4:49:36 PM EDT Loading Chart for MNKD ...

Also backs Ofev as first drug for rare lung disease Meanwhile, NICE has also recommended Boehringer Ingelheim's Ofev (nintedanib) for adult patients with chronic fibrosing interstitial lung ...

making the drug a potential successor to its $3.6 billion-a-year blockbuster IPF therapy Ofev (nintedanib). Topline data from FIBRONEER-ILD showed that nerandomilast met its primary endpoint ...